|
Serious bleeding and mortality rates in DrotAA-treated adults by baseline disease severity |
||
| Period and type of event |
No PF, MEN, or MD N = 3,088 |
PF, MEN, or MD N = 1371 |
|
|
||
| 28-day mortality |
||
| APACHE II |
||
| ≥ 25 |
35.3 (433/1,227) |
22.5 (11/49) |
| <25 |
19.1 (355/1,861) |
12.5 (11/88) |
| Number of organ failures |
||
| ≥ 2 |
27.3 (693/2,538) |
17.8 (18/101) |
| <2 |
17.3 (95/550) |
11.1 (4/36) |
| SBEs during infusion |
||
| APACHE II |
||
| ≥ 25 |
3.7 (45/1,227) |
4.1 (2/49) |
| <25 |
3.0 (55/1,861) |
3.4 (3/88) |
| Number of organ failures |
||
| ≥ 2 |
3.4 (85/2,538) |
4.0 (4/101) |
| <2 |
2.7 (15/550) |
2.8 (1/36) |
| SBEs, 28-day |
||
| APACHE II |
||
| ≥ 25 |
6.2 (76/1,227) |
6.1 (3/49) |
| <25 |
5.5 (102/1,861) |
4.6 (4/88) |
| Number of organ failures |
||
| ≥ 2 |
6.0 (151/2,538) |
5.0 (5/101) |
| <2 |
4.9 (27/550) |
5.6 (2/36) |
|
1Baseline APACHE II and baseline organ dysfunction data available for 137 patients (not collected for the 26 DrotAA-treated adults from the compassionate-use open-label EVAS trial. APACHE, Acute Physiology and Chronic Health Evaluation; DrotAA, drotrecogin alfa (activated); MD, meningococcal disease; MEN, meningitis; PF, purpura fulminans; SBE, serious bleeding event. | ||
Vincent et al. Critical Care 2005 9:R331 doi:10.1186/cc3538 |
||